PMID: 706Oct 14, 1975

The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo

J Gerlach, K Lühdorf


Thirteen out of 18 young out-patients with simple schizophrenia under neuroleptic treatment completed a double-blind cross-over trial with Madopar [L-Dopa + benserazid (a peripheral decarboxylase inhibitor)] and placebo. Nine patients were given 900 mg L-Dopa + 225 mg benserazid daily, 1 patient received 600 mg L-Dopa + 150 mg benserazid, and 3 patients, 300 mg L-Dopa + 75 mg benserazid. In these doses, L-Dopa was effective against emotional withdrawal, blunted affect, tendency to isolation and apathy, without inducing or aggravating productive, accessory symptoms. The activity score, according to the specific activity-withdrawal scale, was significantly increased (P less than 0.05), whereas the total BPRS score (Brief Psychiatric Rating Scale) was slightly, but significantly reduced (P less than 0.05). In cases where L-Dopa had to be limited to 600 and 300 mg daily, a tendency to anxiety, distortion of thinking, and a sense of unreality were observed, depending on the dose of L-Dopa. In no case were gastrointestinal, cardiovascular or neurological side-effects observed.


Aug 1, 1973·Archives of General Psychiatry·J R Stevens
Dec 1, 1973·The Journal of Nervous and Mental Disease·M RiklanD Weissman
Jul 4, 1973·Psychopharmacologia·B AngristS Gershon
Jan 1, 1972·Psychopharmacologia·D L Murphy, G M Henry
Sep 13, 1974·Brain Research·C D MarsdenD Tarsy
Dec 27, 1971·JAMA : the Journal of the American Medical Association·F K Goodwin
Dec 27, 1971·JAMA : the Journal of the American Medical Association·G C Cotzias
Jan 1, 1966·Acta Psychiatrica Scandinavica·A Bruno, S C Bruno
Sep 1, 1970·Archives of Neurology·G G Celesia, A N Barr
Jan 1, 1957·The Journal of Mental Science·P H VENABLES


Jan 1, 1982·Psychopharmacology·B AngristJ Rotrosen
Jan 1, 1989·The Psychiatric Quarterly·S J Bartels, R E Drake
Jan 1, 1993·Journal of Neural Transmission. General Section·A A Grace
Jan 1, 1994·Comprehensive Psychiatry·L A OplerP M Ramirez
Jan 1, 1994·Neuroscience and Biobehavioral Reviews·J L Cadet, L A Kahler
Jan 1, 1987·Progress in Neuro-psychopharmacology & Biological Psychiatry·T A Ban
Jan 1, 1992·Progress in Neuro-psychopharmacology & Biological Psychiatry·M R Lynch
Jan 1, 1979·Psychoneuroendocrinology·D P van Kammen
Jan 1, 1981·Psychoneuroendocrinology·H Y MeltzerV S Fang
Jan 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·O BenkertH Wetzel
Jan 1, 1995·Acta Psychiatrica Scandinavica. Supplementum·J P Lindenmayer
Aug 3, 2012·Revista de psiquiatrí́a y salud mental·José Martínez SerranoJuana González Matás
Jan 1, 1982·Progress in Neuro-psychopharmacology & Biological Psychiatry·G Chouinard, S Steinberg
Nov 12, 2013·Schizophrenia Research·Gary RemingtonMargaret Hahn
Jan 1, 1985·International Journal of Psychiatry in Medicine·S R Kay, L A Opler
Oct 1, 1977·Biochemical Pharmacology·P Seeman
Jan 1, 1994·Journal of Psychopharmacology·D G OwensE C Johnstone
Nov 1, 1990·The International Journal of Neuroscience·R Sandyk, S R Kay
Jan 1, 1989·The Journal of Psychology·J B Murray
Nov 1, 1979·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·G Chouinard, B D Jones
Oct 16, 1989·The Medical Journal of Australia·N A KeksD L Copolov

Related Concepts

Mood (Psychological Function)
Lenticulostriate Disorders
Ro 4-4602
Clinical Trials
Drug Combinations
Brief Psychiatric Rating Scale

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.